AYTU BIOPHARMA, INC Noncash Merger Related Costs
AYTU BIOPHARMA, INC (AYTU) reported Noncash Merger Related Costs of $1.90 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-08-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2017-08-31
- AYTU BIOPHARMA, INC noncash merger related costs for fiscal 2017 was $1.90M.
| Period end | Noncash Merger Related Costs 12 month |
|---|---|
| 2017-06-30 | $1.90M 10-K · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |